Macrophage/foam cells and
cholesterol crystals (CCs) have been regarded as the central triggers of maladaptive
inflammation in
atherosclerotic plaque. Despite the tremendous progress of recombinant
high-density lipoprotein (rHDL) serving for targeted drug delivery to alleviate
inflammation in macrophage/foam cells, the active attempt to modulate/improve its CCs dissolution capacity remains poorly explored. The untreated CCs can seriously aggravate
inflammation and threaten plaque stability. Based on the superb ability of β-
cyclodextrin (β-CD) to bind CCs and promote
cholesterol efflux,
simvastatin-loaded discoidal-rHDL (ST-d-rHDL) anchored with β-CD (βCD-ST-d-rHDL) was constructed. We verified that βCD-ST-d-rHDL specifically bound and dissolved CCs extracellularly and intracellularly. Furthermore, anchoring β-CD onto the surface of ST-d-rHDL enhanced its
cholesterol removal ability in RAW 264.7 cell-derived foam cells characterized by accelerated
cholesterol efflux, reduced intracellular
lipid deposition, and improved cell membrane fluidity/permeability. Finally, βCD-ST-d-rHDL exerted efficient drug delivery and effective anti-inflammatory effects in macrophage/foam cells. Collectively, anchoring β-CD onto the surface of ST-d-rHDL for selective CCs dissolution, accelerated
cholesterol efflux, and improved drug delivery represents an effective strategy to enhance anti-inflammatory effects for the
therapy of
atherosclerosis.